Products & Outsourced Services


EUGENEX Biotechnologies is a Swiss-based company specializing in the generation of high-level expression cell lines and processes for commercial manufacturing of novel biopharmaceuticals and biosimilars. With more than 20 years of experience in mammalian cell culture and process development, EUGENEX Biotechnologies covers the entire drug development chain from cell line to process development for large-scale GMP manufacturing. The EUGENEX team also provides clients patent and regulatory expertise in the field of biosimilars. EUGENEX has developed a wide portfolio of stable, high-expressing cell lines for the production of over 45 biopharmaceuticals such as monoclonal antibodies, fusion proteins, and enzymes. In addition to biosimilar development and contract production, EUGENEX engages in the co-development of new pharmaceutical drugs. Many biopharmaceuticals generated by EUGENEX have been approved by several authorities and have reached markets worldwide including EU and USA. 

EUGENEX’s broad portfolio of cell lines and processes for biosimilar manufacturing includes Recombinant Proteins like EPO, DPO, INFβ, FSH, hLH, hCG, TNK-tPA, FVIIII, Corifolitropin alpha, Dornase α etc.

  • Antibodies like Nivolumab, Daratumumab, Eculizumab, Tocilizumab, Cetuximab, Trastuzumab, Panitumumab, Obinutuzumab, Bevacizumab etc.
  • Fusion Proteins like Etanercept, Abatacept, Belatacept, Dulaglutid
  • Growth Factors, Hormones and Cytokines like PDGF-AB, G-CSF, Interleukin-2, GM-CSF, Somatropin, Interferon- α2, BMP-7 etc.